The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Is there a Avacta telegram group ? 🤔
?
4 partnerships announced
3 x TR1’s
2 formal bidders
1 takeover offer!
And at least one very happy shareholder! 🎄 😀
The RNS dated 19 Sept identified cohort 7 to be the final dose escalation in the phase 1a escalation study. So the review of phase 1s data should include that data and I’m hopeful that at least one more patient will have demonstrated shrinkage of their tumour. That should then make for a welcome news report. GLA
I think fizzy might be in order 🥂 5rings!
Thank you jdt1990 appreciate the reminder 👍🏻
Detailed review of Phase 1a data. The aim of phase 1a was to identify the dosage to be used for phase 1b. So at the least I’d expect that news. Having a MTD confirmed should help to shake the market awake to what’s going on here.
Unless of course they do turn up in Ribena costumes and admit it’s all a hoax? 😂
Kingalf Let’s hope for the ‘potential bullish reversal’ becoming a reality today!
Either way I’ve faith it will get a lot higher than it is at present but I think it’s just a question of when the value here gets recognised by the market. Might have to wait for an inflection point of actual sales figures and confirmation of further approved use (NHS Episwitch?) of the various tests.
It’s like blackadder Kate short for ‘bob’ 😂
But how much would you put on Avacta timing data release to coincide with the webinar Timster?
Interesting contribution Energyshares. Having followed the link it seems any IND has to have completed the phase 1 trial to be eligible. So while AVA6000 wouldn’t at present meet that requirement it would as soon as it does complete phase 1. Another route (besides AA and breakout designation?) to getting AVA6000 into those that need it.
Could we see the AVACTA announce completion of Phase 1 prior to it and then the London conference state AVA6000 is eligible under that program?
If they replicate the tumour shrinkage already announced in one patient with STS (they announced at the same time the data we are awaiting also showed additional signs of efficacy in other patients), then IMHO demand will increase exponentially. The FDA could fast track AVA6000 very quickly and big Pharma would be like Kodak faced with the choice of embracing the new tech or ignoring this.
Thanks Dug. From my quick listen it seems like this additional data will add to the library on which OBD’s tests are based (about 10:50 in on the audio). So Biobank’s news is in general a positive for us.
Biobank has released data that could be used to predict someone’s risk of disease they recruited half a million people to create a comprehensive source of health data. After five years, more than 350,000 hours of genome sequencing, and more than £200 million of investment, it has released the world’s largest single set of sequencing data. Do we think this backs up our tests? Or I does it negate them?
🪄 ✨ They're hard at work ‘just getting on with it’ and soon we will see exactly what they’ve been working on without the RNS wrappers! 🎁
Let’s hope we get the reward that we faithful believers in the ‘big guy’ have been promised. It is the commercialisation season after all! GLA
I think we are due the news we have been waiting on very soon. Hence my top up this morning which is showing as a sell ( 10:06:34 138.45 1,438 Sell* 1,991). Would have been nicer to top up a little bit lower (like I did last week at 1.29) but I’m happy with my holding here. GLALTH 👍🏻
That’s very narrow minded Slacker246. The potential market in the UK if the PSE test were to be used as part of a national screening program is not inconsiderable and the adoption of such a test would be a way to introduce consideration of the other company products.
I’ve emailed the company myself and will share the reply I get.
Thanks for your contributions DugWalker.
It would be great if the company announced they were participating in the Transform trial or at least answer if not why not? If emailed would they need to answer via an RNS?
I think that the PSE test is good enough to be part of a national screening program and certainly very valuable from individual patients point of view. IMHO this will be a key revenue generator for the company and a gateway to the other tests the company has. So I’m invested and holding here.
I know enough to be invested here! 😀 GLA
So we are awaiting the full release of the data from the AVA6000 trial so far which is being done to show the wider communities Pharma and II what is behind and backs up the hyperbole in the previous company statements. If (as expected) this is as good as we faithful SH think then what do we think will be next? Partnership agreements? Licensing agreements? A TO offer? Some TR1’s? 🤔